0001209191-21-061153.txt : 20211020 0001209191-21-061153.hdr.sgml : 20211020 20211020163201 ACCESSION NUMBER: 0001209191-21-061153 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211018 FILED AS OF DATE: 20211020 DATE AS OF CHANGE: 20211020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LINK WILLIAM J PHD CENTRAL INDEX KEY: 0001228684 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 211334542 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-18 0 0001720725 Oyster Point Pharma, Inc. OYST 0001228684 LINK WILLIAM J PHD C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON NJ 08540 1 0 0 0 Common Stock 2021-10-18 4 S 0 303614 14.6327 D 1057976 I See Footnote Common Stock 2021-10-18 4 S 0 242943 15.0939 D 815033 I See Footnote Common Stock 2021-10-18 4 S 0 1912 14.6327 D 6518 I See Footnote Common Stock 2021-10-18 4 S 0 1531 15.0939 D 4987 I See Footnote Common Stock 10066 D Common Stock 20604 I By Limited Partnership Common Stock 1273 I By Trust Common Stock 27942 I By LLC The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by each of Versant Venture Capital IV, L.P. ("Versant IV") and Versant Side Fund IV, L.P. ("Versant Side Fund IV"). The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $14.00 to $14.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote to this Form 4. Shares held by Versant IV. The Reporting Person may be deemed to beneficially own the shares held by Versant IV as a managing member of Versant Ventures IV, LLC ("Versant Ventures IV"), its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $15.00 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote to this Form 4. Shares held by Versant Side Fund IV. The Reporting Person may be deemed to beneficially own the shares held by Versant Side Fund IV as a managing member of Versant Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant Side Fund IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP. Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust. Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC. /s/ Brandon Fenn, Attorney-in-Fact 2021-10-20